2012
DNA repair metagene signature as a prognostic and predictive factor in molecular breast cancer subtypes.
Santarpia L, Iwamoto T, Di Leo A, Hayashi N, Stampfer M, Guarducci C, Symmans W, Hortobagyi G, Pusztai L, Giampaolo B. DNA repair metagene signature as a prognostic and predictive factor in molecular breast cancer subtypes. Journal Of Clinical Oncology 2012, 30: 1012-1012. DOI: 10.1200/jco.2012.30.15_suppl.1012.Peer-Reviewed Original ResearchPathological complete responseHigher pathological complete responseBreast cancer molecular subtypesTaxane-based regimensTaxane-containing regimensCisplatin-containing regimensMolecular breast cancer subtypesTaxane-based chemotherapyPotential predictive markerBreast cancer subtypesCancer molecular subtypesBC cell linesFalse discovery correctionDistant relapseComplete responseBetter prognosisPoor prognosisPredictive factorsPrognostic valueBC subtypesER-/HER2Predictive markerN patientsPrognostic markerMolecular subtypes
2009
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer
Caudle A, Gonzalez-Angulo A, Kelly H, Liu P, Pusztai L, Symmans W, Kuerer H, Mittendorf E, Hortobagyi G, Meric-Bernstam F. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. Journal Of Clinical Oncology 2009, 27: 603-603. DOI: 10.1200/jco.2009.27.15_suppl.603.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyHigh Ki-67High tumor gradeStable diseasePR statusBreast cancerTumor gradeKi-67Negative ERNegative ER/PR statusFirst-line surgical approachSingle comprehensive cancer centerTumor progressionER/PR statusTaxane-based regimensComplete pathologic responseSubset of patientsLymph node metastasisHigher T stageComprehensive cancer centerPre-treatment characteristicsNCT regimenLymphovascular invasionMost patientsPathologic response